Compare the pathways of imported versus indigenous vaccine development in India, citing the Qdenga and DengiAll examples.

Q. Compare the pathways of imported versus indigenous vaccine development in India, citing the Qdenga and DengiAll examples. (15 marks, 250-350 words)

Dengue remains one of India's heaviest vector-borne disease burdens, with over 2.33 lakh cases reported in 2024 [3]. India's response reveals two parallel vaccine pathways — the import-and-approve route, seen in CDSCO's July 2026 marketing authorisation of Takeda's Qdenga® [1], and the indigenous development route of DengiAll by ICMR–Panacea Biotec [2].

Regulatory and development pathway - Imported route: Qdenga arrived with a global evidence base — approvals in 42 countries and WHO prequalification — requiring CDSCO only to bridge it with a Phase III safety and immunogenicity study in the Indian population under the Drugs and Cosmetics Act, 1940 [1]. - Indigenous route: DengiAll must traverse the full ladder — Phase 1/2 (completed 2018–19) to a Phase 3 efficacy trial across 19 sites in 18 States/UTs with over 10,335 participants, with two-year follow-up [2].

Speed versus self-reliance - Import compresses time-to-availability; a proven tetravalent vaccine with 24 million doses distributed globally became accessible for ages 4–60 within months of dossier review [1]. - Indigenisation is slower but builds domestic manufacturing depth, using the NIH-derived TV003/TV005 strain adapted by an Indian firm [2] — advancing Atmanirbhar Bharat in biopharma.

Cost, access and supply security - Imported vaccines carry foreign-exchange costs and are typically confined to the private market, limiting equity. - An indigenous, ICMR-funded candidate offers price control and assured supply, easing integration into the National Vector Borne Diseases Control framework [3].

Evidence fit - Global trial populations may not fully mirror India's serotype mix; DengiAll's India-wide trial generates directly applicable efficacy data [2].

The two pathways are complementary rather than competing: imports deliver immediate protection while indigenous R&D secures long-term affordability and sovereignty. India should therefore use Qdenga to blunt the present outbreak burden, while strengthening ICMR-led trials, regulatory capacity in CDSCO and domestic manufacturing — converting a stopgap import into durable public-health self-reliance aligned with SDG-3.

(~320 words)

Sources: 1. CDSCO Approves India's First Dengue Vaccine, Strengthening National Dengue Prevention Efforts — PIB (21 July 2026) — Qdenga approval, Takeda GmbH, ages 4–60, Drugs and Cosmetics Act 1940, Indian Phase III bridging study, 42 countries, WHO prequalification, 24 million doses 2. ICMR and Panacea Biotec initiate the First Dengue Vaccine Phase 3 Clinical Trial in India with Indigenous Dengue Vaccine, DengiAll — PIB — DengiAll Phase 3 across 19 sites in 18 States/UTs, 10,335+ participants, Phase 1/2 completed 2018–19, TV003/TV005 strain, ICMR funding 3. Dengue Situation in India — National Center for Vector Borne Diseases Control, MoHFW — 2024 dengue case burden and national vector-borne disease control framework